Press Release
ATAI launches IntroSpect Digital Therapeutics, appoints veteran software engineer David Keene as CEO
LONDON and NEW YORK, June 22, 2020 /PRNewswire/ -- Today, ATAI Life Sciences ("ATAI" or the "Company") , a global biotech developing psychedelic and non-psychedelic compounds for various mental health indications, announced the launch of its digital therapeutic platform IntroSpect Digital
Press Release
ATAI Life Sciences announces close of $24 million convertible note financing round and welcomes Jason Camm of Thiel Capital to Board of Directors
LONDON and NEW YORK, April 23, 2020 /PRNewswire/ -- ATAI Life Sciences ("ATAI" or the "Company") ,  a global biotechnology company builder founded by Christian Angermayer that envisions an end to mental illnesses, today announced the close of a $24 million convertible note financing round.
Press Release
ATAI Life Sciences Announces Joint Venture with DemeRx to Develop Ibogaine For Opioid Use Disorder
BERLIN and MIAMI, Jan. 24, 2020 /PRNewswire/ --   ATAI Life Sciences AG  ("ATAI" or the "Company"),  a global biotech platform that envisions an end to mental illnesses, today announced an investment in two separate joint ventures (JV) with DemeRx, a clinical stage pharmaceutical company focused on
Press Release
ATAI Life Sciences Announces Joint Venture with DemeRx to Develop Ibogaine For Opioid Use Disorder
BERLIN and MIAMI, Jan. 24, 2020 /PRNewswire/ --   ATAI Life Sciences AG  ("ATAI" or the "Company"),  a global biotech platform that envisions an end to mental illnesses, today announced an investment in two separate joint ventures (JV) with DemeRx, a clinical stage pharmaceutical company focused on
Press Release
ATAI Life Sciences Partners with Neuronasal Inc. to Develop Novel Treatment for mild Traumatic Brain Injury (mTBI)
BERLIN and WEXFORD, Pa., Jan. 6, 2020 /PRNewswire/ -- ATAI Life Sciences AG ("ATAI" or the "Company") , a global biotech platform that envisions an end to mental illnesses, today announced that it has partnered with Neuronasal Inc., to develop a short-term treatment for mild Traumatic Brain Injury
Press Release
GABA Therapeutics and ATAI Life Sciences Partner to Develop a Novel GABA Modulator for the Treatment of Mood Disorders
NEWPORT BEACH, Calif. and BERLIN, Sept. 20, 2019 /PRNewswire/ -- Today, GABA Therapeutics , a biotech company focused on the treatment of mood disorders, and ATAI Life Sciences , a global biotech company builder working on paradigm shifting interventions for unmet needs in the mental health space,
Displaying 73 - 78 of 78